Literature DB >> 9126600

Rapid generation of stable cell lines expressing corticotropin-releasing hormone receptor for drug discovery.

R A Horlick1, K Sperle, L A Breth, C C Reid, E S Shen, A K Robbins, G M Cooke, B L Largent.   

Abstract

Human HEK293 cells that stably express the Epstein Barr nuclear antigen 1 (EBNA1) support the episomal replication of plasmids containing the Epstein Barr virus origin of replication (EBV oriP). A 293EBNA (293E) cell line expressing the human corticotropin-releasing hormone receptor subtype I (CRHR1) from an episomal plasmid was generated (293CR1s), analyzed, adapted to spinner culture, and scaled-up for production in less than 6 weeks. Forty-seven stable CHO cell lines transfected with CRHR1 were also isolated. Expression of the receptor in the best of these lines (as judged by CRH-induced cAMP production), CHO-R22, was compared to that in 293CR1s cells. Results indicate that the CRHR1 episomal expression vector in 293E cells (1) rapidly generates stable cell lines suitable for scale-up; (2) is stably maintained during 3 months in culture; (3) expresses high levels of CRHR1 mRNA; and (4) expresses significantly more CRHR1 than the CHO-R22 line. Coexpression of additional G protein alpha subunit (G alpha s) with CRHR1 in 293E cells converts a higher percentage of receptor to the agonist high-affinity G-protein-coupled state. Our data support the idea that using the EBV oriP-driven episomal system for gene expression results in greater production of protein in a relatively short period of time.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126600     DOI: 10.1006/prep.1996.0701

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  2 in total

1.  Effects of pCIneo and pCEP4 expression vectors on transient and stable protein production in human and simian cell lines.

Authors:  J H Parham; T Kost; J T Hutchins
Journal:  Cytotechnology       Date:  2001-05       Impact factor: 2.058

Review 2.  The other side of the coin: Leveraging Epstein-Barr virus in research and therapy.

Authors:  Fenggang Yu; Wei Jian Tan; Yanan Lu; Paul A MacAry; Kwok Seng Loh
Journal:  Oral Oncol       Date:  2016-07-21       Impact factor: 5.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.